Community stack
GH Starter Stack
CJC-1295 + Ipamorelin
This is the standard entry-level growth-hormone secretagogue pairing in peptide communities, used for body composition, recovery and general anti-aging goals by raising the body's own GH pulses rather than injecting GH directly. Vendor guides also attach broader claims (fat loss, skin, cognition, energy) that go beyond what either compound's own human research directly supports. Community sources use several different names for the same CJC-1295 (no DAC) + Ipamorelin pairing - 'GH Pulse Stack' (Peptide Dosing Protocols) and 'The Dynamic Duo' (Muscle & Brawn) both refer to it.
Community stack - not clinically tested
No clinical trial has tested this exact combination. The rationale below is built from each compound's individual research, and the dosing is community-derived. None of these compounds is FDA-approved for this use.
What is in it
Why people run it
The mechanism is receptor-based and consistent across both sources: CJC-1295 without DAC is a GHRH-receptor analog that mimics the hypothalamus's own signal telling the pituitary to release GH, while Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that triggers GH release through a separate pathway on the same pituitary cells. Peptide Dosing Protocols cites cellular research that 'ghrelin-receptor signaling potentiates GHRH-receptor signaling,' framing the combination as more than simply additive; Muscle & Brawn puts it more loosely as Ipamorelin triggering 'pulsatile GH release' while CJC-1295 'extends the overall duration of GH secretion.' This rationale is grounded in each compound's separately studied receptor pharmacology and human PK data, but neither source claims the two-peptide combination itself has been tested this way in people.
Community dosing
communityThe two guides converge closely: 100-300 mcg of each peptide, subcutaneous, commonly on an empty stomach before bed, with maintenance often settling around 200 mcg each; Muscle & Brawn instead describes splitting into 2-3 times daily dosing rather than once daily. Peptide Dosing Protocols cites a 20 mg combined-blend vial with 3 mL bacteriostatic water (3.33 mg/mL of each peptide) as one reconstitution approach. Cycles commonly run 8-12 weeks on, followed by about 4 weeks off.
Work out your draw in the calculatorThe honest caveat
Peptide Dosing Protocols states directly that 'No published human randomized trial has evaluated the CJC-1295 (no DAC) + Ipamorelin combination' at the doses common in community use. Muscle & Brawn does not claim trial evidence for the combination either. Both individual peptides have real but narrow human data (short single-dose PK/safety studies) - the daily self-injection protocol and the pairing itself are community-developed, not clinically established. Neither compound is FDA-approved, and CJC-1295 is WADA-prohibited.
Sources
- [1]CJC-1295 + Ipamorelin Peptide Dosing Guide: Protocol, Timing and CycleNames the pairing the 'CJC-1295 + Ipamorelin GH Pulse Stack'; explains the GHRH-receptor vs ghrelin-receptor mechanism and cites research that ghrelin-receptor signaling potentiates GHRH-receptor signaling; states 'No published human randomized trial has evaluated the CJC-1295 (no DAC) + Ipamorelin combination' at community-used doses; gives dosing (100-300 mcg each daily, 8-12 weeks on/4 off) and reconstitution (20 mg blend + 3 mL bacteriostatic water).
- [2]Ipamorelin + CJC 1295 Stack: The Dynamic DuoDescribes the combination as 'The Dynamic Duo,' with Ipamorelin triggering pulsatile GH release while CJC-1295 extends the duration of GH secretion; gives community dosing (CJC-1295 no-DAC and Ipamorelin each 100-300 mcg, 2-3 times daily, 8-12 week cycles) and states both are 'research chemicals... not approved by regulatory bodies like the FDA.'
Other stacks